Published in Clin Cancer Res on August 01, 2001
Epigenetic modifications as therapeutic targets. Nat Biotechnol (2010) 3.16
Leukaemogenesis: more than mutant genes. Nat Rev Cancer (2010) 2.16
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood (2007) 2.15
Cancer epigenetics: linking basic biology to clinical medicine. Cell Res (2011) 1.88
Phenylbutyrate induces antimicrobial peptide expression. Antimicrob Agents Chemother (2009) 1.21
Epigenetics as a therapeutic target in breast cancer. J Mammary Gland Biol Neoplasia (2012) 1.05
Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches. Cancer Control (2008) 1.05
Targeting histone deacetylases for the treatment of disease. J Cell Mol Med (2008) 0.94
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio. Mol Genet Metab (2013) 0.92
Epigenetic therapy of leukemia: An update. Int J Biochem Cell Biol (2008) 0.92
Evidence for involvement of medium chain acyl-CoA dehydrogenase in the metabolism of phenylbutyrate. Mol Genet Metab (2012) 0.87
Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias. Curr Med Chem (2008) 0.85
Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"? J Biomed Biotechnol (2011) 0.83
DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer Epigenetics. Scientifica (Cairo) (2016) 0.76
Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia. Clin Epigenetics (2015) 0.75
Role of epigenetic therapy in myelodysplastic syndrome. Expert Rev Hematol (2008) 0.75
Identification of enzymes involved in oxidation of phenylbutyrate. J Lipid Res (2017) 0.75
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med (1995) 13.59
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood (1996) 13.35
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (1999) 9.22
Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg (1997) 8.86
Paclitaxel (taxol) N Engl J Med (1995) 5.79
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol (2001) 5.17
Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg (1997) 3.90
Hypersensitivity reactions from taxol. J Clin Oncol (1990) 3.83
ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol (2001) 3.55
Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res (1999) 3.46
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene (2000) 3.40
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol (2001) 3.27
Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother (1993) 3.25
Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol (1993) 3.18
Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood (1992) 3.09
Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst (1990) 3.09
Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood (1995) 2.82
Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med (1989) 2.81
Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis (1998) 2.78
Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood (1999) 2.66
Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics (1992) 2.55
Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood (1997) 2.55
Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. N Engl J Med (1993) 2.50
OATP1B1 polymorphism as a determinant of erythromycin disposition. Clin Pharmacol Ther (2012) 2.43
A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol (2010) 2.39
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer (2003) 2.38
A new primary effusion lymphoma-derived cell line yields a highly infectious Kaposi's sarcoma herpesvirus-containing supernatant. J Virol (2000) 2.37
Venoocclusive disease of the liver following bone marrow transplantation. Transplantation (1987) 2.35
Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci U S A (2000) 2.23
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol (2000) 2.22
Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst (1996) 2.21
Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst (1996) 2.20
Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer. J Natl Cancer Inst (1990) 2.15
Regional chemotherapy devices: effect of experience and anatomy on complications. J Clin Oncol (1993) 2.09
The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol Ther (1991) 2.06
Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies. N Engl J Med (1995) 2.05
Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J Sci Am (1998) 2.03
Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res (1999) 2.02
Successful re-treatment with taxol after major hypersensitivity reactions. J Clin Oncol (1993) 2.00
Origin of the beta S-globin gene in blacks: the contribution of recurrent mutation or gene conversion or both. Proc Natl Acad Sci U S A (1984) 2.00
Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res (1988) 1.99
Acute bilineal leukemia: a rare disease with poor outcome. Leukemia (2007) 1.98
Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine (Baltimore) (1996) 1.90
Expression of AT2 receptors in the developing rat fetus. J Clin Invest (1991) 1.89
The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst (1993) 1.84
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res (1996) 1.82
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol (1998) 1.80
Molecular defect of the band 3 protein in southeast Asian ovalocytosis. N Engl J Med (1990) 1.77
Characterization of mouse lymphohematopoietic stem cells lacking spleen colony-forming activity. Blood (1996) 1.76
Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation. J Clin Oncol (1995) 1.71
Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol (1994) 1.70
Binding of beta-amyloid to the p75 neurotrophin receptor induces apoptosis. A possible mechanism for Alzheimer's disease. J Clin Invest (1997) 1.66
Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res (1999) 1.64
Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. N Engl J Med (1990) 1.63
Individual variation in the production and survival of F cells in sickle-cell disease. N Engl J Med (1978) 1.59
Deletion in erythrocyte band 3 gene in malaria-resistant Southeast Asian ovalocytosis. Proc Natl Acad Sci U S A (1991) 1.59
Blastic natural killer cell leukemia/lymphoma: a clinicopathologic study. Am J Surg Pathol (1997) 1.58
Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol (1994) 1.57
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. J Clin Oncol (1999) 1.56
Neurotoxicity of Taxol. J Natl Cancer Inst Monogr (1993) 1.53
Should pancreaticoduodenectomy be performed in octogenarians? J Gastrointest Surg (1999) 1.53
F-cell production in sickle cell anemia: regulation by genes linked to beta-hemoglobin locus. Science (1981) 1.51
Hydroxyurea-induced HbF production in anemic primates: augmentation by erythropoietin, hematopoietic growth factors, and sodium butyrate. Exp Hematol (1992) 1.50
Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol (1991) 1.49
A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res (2001) 1.49
Treatment of sickle cell anemia with hydroxyurea and erythropoietin. N Engl J Med (1990) 1.47
Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol (1998) 1.46
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol (1992) 1.46
Cardiac disturbances during the administration of taxol. J Clin Oncol (1991) 1.46
Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin Proc (1999) 1.46
A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors. Clin Cancer Res (2000) 1.45
Isolation and characterization of the human cytochrome P450 CYP1B1 gene. J Biol Chem (1996) 1.44
A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia. Clin Cancer Res (1998) 1.42
Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol (1998) 1.42
Normal fetal hemoglobin levels in the sudden infant death syndrome. N Engl J Med (1989) 1.42
Chromosome abnormalities in pediatric brain tumors. Cancer Res (1988) 1.42
Heterogeneity of chromosome 22 breakpoint in Philadelphia-positive (Ph+) acute lymphocytic leukemia. Proc Natl Acad Sci U S A (1986) 1.41
Human collagen genes encoding basement membrane alpha 1 (IV) and alpha 2 (IV) chains map to the distal long arm of chromosome 13. Proc Natl Acad Sci U S A (1987) 1.41
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol (2001) 1.41
Clinical and pharmacologic reappraisal of dichloromethotrexate. J Natl Cancer Inst (1988) 1.40